Highlights in HR-Positive Breast Cancer From SABCS 2023 Highlights in HR-Positive Breast Cancer From SABCS 2023

Highlights in HR+/HER2- breast cancer from SABCS 2023 include the INAVO120 trial of novel PI3K inhibitor inavolisib and 3-year follow-up data from the NATALEE trial, as reported by Dr Harold Burstein.Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news